Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
61/99

BSE: 532531 | NSE: STAR

NSE BSE
936.45
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  953.10
  •  964.80
  •  931.00
  •  950.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  156186
  •  1478.22
  •  1032.00
  •  412.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 9,393.89
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,617.25
  • 0.24%
  • 4.42

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 25.86%
  • 3.73%
  • 20.87%
  • FII
  • DII
  • Others
  • 26.71%
  • 17.05%
  • 5.78%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.65
  • 3.48
  • 3.61

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.60
  • 5.37
  • -9.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -48.42
  • -46.85
  • -60.89

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.86
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.14
  • 1.95
  • 1.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.56
  • 15.86
  • 18.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
1,084.04
986.37
9.90%
1,037.67
864.85
19.98%
999.43
897.10
11.41%
929.99
940.07
-1.07%
Expenses
854.30
830.81
2.83%
843.86
748.50
12.74%
846.30
798.97
5.92%
763.40
879.92
-13.24%
EBITDA
229.73
155.56
47.68%
193.81
116.34
66.59%
153.13
98.13
56.05%
166.59
60.15
176.96%
EBIDTM
21.19%
15.77%
18.68%
13.45%
15.32%
10.94%
17.91%
6.40%
Other Income
-13.55
27.12
-
8.75
26.20
-66.60%
35.85
23.46
52.81%
8.64
13.55
-36.24%
Interest
80.16
80.52
-0.45%
79.28
58.44
35.66%
78.59
67.64
16.19%
76.42
54.54
40.12%
Depreciation
49.76
60.93
-18.33%
51.23
60.22
-14.93%
60.10
61.70
-2.59%
59.59
60.40
-1.34%
PBT
78.20
33.89
130.75%
61.99
65.44
-5.27%
-114.64
6.77
-
33.25
-107.01
-
Tax
19.25
7.09
171.51%
10.10
4.09
146.94%
-7.44
-38.40
-
9.68
-28.07
-
PAT
58.95
26.81
119.88%
51.88
61.35
-15.44%
-107.20
45.17
-
23.57
-78.94
-
PATM
5.44%
2.72%
5.00%
7.09%
-10.73%
5.04%
2.53%
-8.40%
EPS
1.98
-1.06
-
5.41
-8.86
-
-14.54
2.53
-
-0.79
-15.13
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
4,051.13
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
Net Sales Growth
9.83%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
 
Cost Of Goods Sold
1,640.51
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
Gross Profit
2,410.62
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
GP Margin
59.50%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
Total Expenditure
3,307.86
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
Power & Fuel Cost
-
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
18.56
% Of Sales
-
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
Employee Cost
-
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
157.18
% Of Sales
-
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
Manufacturing Exp.
-
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
35.76
% Of Sales
-
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
General & Admin Exp.
-
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
66.37
% Of Sales
-
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
Selling & Distn. Exp.
-
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
66.67
% Of Sales
-
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
Miscellaneous Exp.
-
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
96.95
29.44
66.67
% Of Sales
-
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
EBITDA
743.26
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
228.85
223.42
EBITDA Margin
18.35%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
Other Income
39.69
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
38.57
60.23
Interest
314.45
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
108.88
Depreciation
220.68
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
56.48
PBT
58.80
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
118.30
Tax
31.59
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
40.86
Tax Rate
53.72%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
PAT
27.20
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
1.57
50.89
PAT before Minority Interest
50.90
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
0.98
50.89
Minority Interest
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
PAT Margin
0.67%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
PAT Growth
-49.99%
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
 
EPS
2.96
-24.07
-50.08
38.34
15.63
40.29
74.14
43.46
12.32
0.17
5.54

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
Share Capital
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
59.57
Total Reserves
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
Non-Current Liabilities
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
Secured Loans
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
Unsecured Loans
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
1.24
Long Term Provisions
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
16.56
Current Liabilities
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
Trade Payables
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
262.31
Other Current Liabilities
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
127.27
Short Term Borrowings
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
Short Term Provisions
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
93.23
Total Liabilities
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
Net Block
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
Gross Block
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
Accumulated Depreciation
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
352.80
Non Current Assets
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
Capital Work in Progress
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
99.47
Non Current Investment
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
68.76
41.80
Long Term Loans & Adv.
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
96.72
90.40
Other Non Current Assets
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
1.91
1.45
Current Assets
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
Current Investments
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
Inventories
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
175.99
Sundry Debtors
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
Cash & Bank
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
231.15
Other Current Assets
322.55
647.90
98.22
83.57
385.98
434.59
454.09
343.44
123.64
136.26
Short Term Loans & Adv.
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
79.06
Net Current Assets
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
Total Assets
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
PBT
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
Adjustment
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
Changes in Working Capital
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
Cash after chg. in Working capital
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
Net Fixed Assets
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
Net Investments
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
Others
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
Cash from Financing Activity
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
Net Cash Inflow / Outflow
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
Opening Cash & Equivalents
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
Closing Cash & Equivalent
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
168.99
ROA
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
ROE
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
ROCE
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
Fixed Asset Turnover
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
0.61
Receivable days
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
114.80
Inventory Days
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
83.78
Payable days
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
112.69
Cash Conversion Cycle
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
Total Debt/Equity
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
0.54
Interest Cover
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85
4.13
1.84

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Strides Pharma Science’s arm incorporates company in New Zealand
    27th Jul 2024, 12:05 PM

    Strides New Zealand shall hold market authorizations for the products in New Zealand and shall also undertake trading in pharmaceutical products

    Read More
  • Strides Pharma Scien - Quarterly Results
    22nd May 2024, 13:43 PM

    Read More
  • Strides Pharma Science’s step-down arm gets USFDA’s approval for Sucralfate Oral Suspension
    22nd May 2024, 10:30 AM

    The product is bioequivalent and therapeutically equivalent to the RLD, Carafate 1gm/10mL of AbbVie

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Sevelamer Carbonate Tablets
    10th May 2024, 14:08 PM

    The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug, Renvela Tablets, 800 mg, of Genzyme

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.